Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Specialty CROs Are the Latest Trend in Services Targets
Contract research organizations (CROs) were huge targets in 2017, with four of the sector’s 10 biggest deals bringing in $22.9 billion, combined. The CRO market has cooled in 2018, but interesting new trends pop up now and then. The latest is the trend toward specialty CROs, which focus on specific areas such as diseases of the central nervous system. In one week in July, two such CROs have traded hands. The first, on July 9, was Oculos Clinical Research, a CRO based in Tampa, Florida that focuses on ophthalmology. Private equity firm Point Guard Partners was exiting, and Iuvo Bioscience, a portfolio company of Tartan Holdings, was investing. Iuvo Bioscience, based in Rush, New... Read More »
Otsuka Scores Twice in One Week
Otsuka Pharmaceutical Co., Ltd., a subsidiary of Otsuka Holdings (OTC: OTSKY), announced back-to-back deals in early July, in which it entered a new field, and bolstered one of its existing segments. Otsuka’s research areas are in psychiatric and neurological diseases, hematological cancers, and kidney, cardiovascular, and infectious diseases. On July 11, the company announced its acquisition of ReCor Medical, a portfolio company of Sofinnova Partners, for an undisclosed price. The Palo Alto, California-based medical device company specializes in the treatment of hypertension, a new area for Otsuka. ReCor was founded in 2009 by Sofinnova Partners and Professor Jacques Seguin, MD, who... Read More »
Health Care M&A Weekly Deals, Week Ending July 6, 2018
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Hospitals Acquirer Target Price ApolloMed Holdings and AMHC Healthcare The French Hospital $33 million Long-Term Care Acquirer Target Price Griffin-American Healthcare REIT IV Pelican Bay Assisted Living & Memory Care $19.5 million... Read More »
Q2:18 Health Care Deal Volume and Value Explode
What a quarter it was. Even with preliminary data, the numbers of deals and dollars spent in the second quarter of 2018 are impressive. The quarter began with a bang in April (176 deals), settled in May (136 deals) and slowed in June (122 deals). That still adds up to 432 transactions reported in the second quarter, up 1% compared with the first quarter, and 13% better than the same quarter in 2017. The Services sectors accounted for 59% of the deal volume in Q1:18, five percentage points lower than in the previous quarter, and three percentage points lower than Q2:17. The Long-Term Care sector, which turned in 47 deals in April alone, posted gains of 28% compared with Q1:18 and 33%... Read More »
June 2018 Deal Volume Settles into Summer Mode
June was a gentle month for deal making. As the first month of summer, preliminary data shows a slight drop in deal volume for the month, compared with a busier May. Investors seem to be taking the adage “Buy in May and go away” seriously. With a preliminary total of 122 transactions made public in June 2018, deal volume was down 10% compared with May’s 135 deals. Deal volume compared to June 2017 was off 8%. Long-Term Care deals, which typically make up the greatest share of monthly volume, were down to just 22 transactions (18% share) compared with 35 in the previous month. That’s the way the second quarter played out in this sector, with April deal volume spiking... Read More »
Catalent Takes Juniper Pharmaceuticals Private
Catalent, Inc. (NASDAQ: CTLT), a contract research organization (CRO), announced its acquisition of thinly traded nano cap Juniper Pharmaceuticals (NASDAQ: JPR) for $139.6 million. Catalent, based in Somerset, New Jersey, offers development services, delivery technologies and supply solutions for drugs and biologics. On a trailing 12-month basis, the company generated revenue of $2.4 billion, and EBITDA of $484.6 million. Juniper, based in Boston, Massachusetts, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women’s health. This deal includes Juniper’s UK-based Juniper Pharma Services division, a high-end CRO. The transaction... Read More »
Boston Scientific Announces Fourth Deal in 2018
In a quiet holiday week, Boston Scientific Corporation (NYSE: BSX) made some news with its $202 million acquisition of privately held Criterion Medical, Inc. Founded in 2016, Criterion Medical has developed a single-shot cryoablation platform for the treatment of atrial fibrillation (AF). Boston Scientific already held a 35% stake in the Carlsbad, California-based company. The $202 million paid for the 65% it didn’t already own. The addition of this cryoballoon platform positions Boston Scientific as the first to have both cryothermal and radiofrequency (RF) single-shot, balloon-based ablation therapies in its portfolio. This is Boston Scientific’s fourth announced acquisition... Read More »
Health Care M&A Weekly Deals, The Week Ending June 29, 2018
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Behavioral Health Care Acquirer Target Price BelHealth Investment Partners Beach House Center for Recovery N/A Biotechnology Acquirer Target Price Akebia Therapeutics, Inc. Keryx Biopharmaceuticals, Inc. Merger Bio-Techne Corporation... Read More »
